An Open-Label, Pilot Trial to Assess the Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage Determined by Low Field Extremity MRI (eMRI) and X-ray.
Phase of Trial: Phase II/III
Latest Information Update: 09 Jun 2014
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 15 Apr 2014 Trial status changed to completed as reported by ClinicalTrials.gov.
- 15 Apr 2011 New trial record